Global Renin-Angiotensin-System (RAS)-Acting Agent Market Research Report 2025(Status and Outlook)

Report Overview

Renin-Angiotensin-System (RAS)-Acting Agents are a class of pharmaceutical drugs that target the renin-angiotensin system in the body. These agents work by either inhibiting the production of renin or blocking the action of angiotensin, which helps regulate blood pressure and fluid balance. RAS-acting agents are commonly used to treat conditions such as hypertension, heart failure, and diabetic nephropathy. By targeting specific components of the renin-angiotensin system, these drugs help to lower blood pressure, reduce the workload on the heart, and improve overall cardiovascular health.

The market for RAS-acting agents is driven by several key factors. Firstly, the high prevalence of hypertension and cardiovascular diseases worldwide has led to a growing demand for effective treatment options such as RAS-acting agents. Additionally, the increasing adoption of these drugs in combination therapy regimens for managing various cardiovascular conditions is contributing to market growth. Moreover, ongoing research and development efforts aimed at expanding the applications of RAS-acting agents are expected to further drive market expansion. With a focus on developing more targeted and efficacious treatments, pharmaceutical companies are investing in innovation within this segment, which is likely to fuel market growth in the coming years.

In addition to these market drivers, the growing geriatric population globally is also expected to significantly impact the market for RAS-acting agents. As the elderly are more prone to hypertension and related cardiovascular conditions, there is a higher demand for effective treatment options in this demographic. Furthermore, increasing awareness about the importance of managing hypertension and cardiovascular health is leading to greater patient compliance with prescribed medications, including RAS-acting agents. Overall, the market for RAS-acting agents is poised for steady growth, driven by a combination of demographic trends, research advancements, and evolving treatment paradigms in cardiovascular care.

The global Renin-Angiotensin-System (RAS)-Acting Agent market size was estimated at USD 633.15 million in 2024 and is projected to reach USD 935.45 million by 2033, exhibiting a CAGR of 5.00% during the forecast period.

This report provides a deep insight into the global Renin-Angiotensin-System (RAS)-Acting Agent market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, PEST analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Renin-Angiotensin-System (RAS)-Acting Agent Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Renin-Angiotensin-System (RAS)-Acting Agent market in any manner.

Global Renin-Angiotensin-System (RAS)-Acting Agent Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Novartis AG

Pfizer

Inc.

AstraZeneca plc

Merck & Co.

Inc.

Sanofi S.A.

Bristol-Myers Squibb Company

Daiichi Sankyo Company,Limited

Takeda Pharmaceutical Company Limited

Boehringer lngelheim GmbH

Johnson & Johnson

Market Segmentation (by Type)

Angiotensin Converting Enzyme Inhibitors (ACEi)

Angiotensin Receptor Blockers (ARBs)

Market Segmentation (by Application)

Hypertension

Heart Failure

Chronic Kidney Disease

Other

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Renin-Angiotensin-System (RAS)-Acting Agent Market

Overview of the regional outlook of the Renin-Angiotensin-System (RAS)-Acting Agent Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Renin-Angiotensin-System (RAS)-Acting Agent Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Renin-Angiotensin-System (RAS)-Acting Agent, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Renin-Angiotensin-System (RAS)-Acting Agent
1.2 Key Market Segments
1.2.1 Renin-Angiotensin-System (RAS)-Acting Agent Segment by Type
1.2.2 Renin-Angiotensin-System (RAS)-Acting Agent Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Renin-Angiotensin-System (RAS)-Acting Agent Market Overview
2.1 Global Market Overview
2.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Renin-Angiotensin-System (RAS)-Acting Agent Market Competitive Landscape
3.1 Company Assessment Quadrant
3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Product Life Cycle
3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Manufacturers (2020-2025)
3.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Manufacturers (2020-2025)
3.5 Renin-Angiotensin-System (RAS)-Acting Agent Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Renin-Angiotensin-System (RAS)-Acting Agent Average Price by Manufacturers (2020-2025)
3.7 Manufacturers Renin-Angiotensin-System (RAS)-Acting Agent Sales Sites, Area Served, Product Type
3.8 Renin-Angiotensin-System (RAS)-Acting Agent Market Competitive Situation and Trends
3.8.1 Renin-Angiotensin-System (RAS)-Acting Agent Market Concentration Rate
3.8.2 Global 5 and 10 Largest Renin-Angiotensin-System (RAS)-Acting Agent Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 Renin-Angiotensin-System (RAS)-Acting Agent Industry Chain Analysis
4.1 Renin-Angiotensin-System (RAS)-Acting Agent Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Renin-Angiotensin-System (RAS)-Acting Agent Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 PEST Analysis
5.6.1 Industry Policies Analysis
5.6.2 Economic Environment Analysis
5.6.3 Social Environment Analysis
5.6.4 Technological Environment Analysis
5.7 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Porter's Five Forces Analysis
5.7.1 Global Trade Frictions
5.7.2 Global Trade Frictions and Their Impacts to Renin-Angiotensin-System (RAS)-Acting Agent Market
5.8 ESG Ratings of Leading Companies
6 Renin-Angiotensin-System (RAS)-Acting Agent Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2020-2025)
6.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Market Share by Type (2020-2025)
6.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Price by Type (2020-2025)
7 Renin-Angiotensin-System (RAS)-Acting Agent Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Sales by Application (2020-2025)
7.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size (M USD) by Application (2020-2025)
7.4 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth Rate by Application (2020-2025)
8 Renin-Angiotensin-System (RAS)-Acting Agent Market Sales by Region
8.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region
8.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region
8.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region
8.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Region
8.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Region
8.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Market Share by Region
8.3 North America
8.3.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country
8.3.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country
8.4.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region
8.5.2 Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country
8.6.2 South America Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region
8.7.2 Middle East and Africa Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 Renin-Angiotensin-System (RAS)-Acting Agent Market Production by Region
9.1 Global Production of Renin-Angiotensin-System (RAS)-Acting Agent by Region(2020-2025)
9.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region (2020-2025)
9.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Renin-Angiotensin-System (RAS)-Acting Agent Production
9.4.1 North America Renin-Angiotensin-System (RAS)-Acting Agent Production Growth Rate (2020-2025)
9.4.2 North America Renin-Angiotensin-System (RAS)-Acting Agent Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Renin-Angiotensin-System (RAS)-Acting Agent Production
9.5.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Production Growth Rate (2020-2025)
9.5.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Renin-Angiotensin-System (RAS)-Acting Agent Production (2020-2025)
9.6.1 Japan Renin-Angiotensin-System (RAS)-Acting Agent Production Growth Rate (2020-2025)
9.6.2 Japan Renin-Angiotensin-System (RAS)-Acting Agent Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Renin-Angiotensin-System (RAS)-Acting Agent Production (2020-2025)
9.7.1 China Renin-Angiotensin-System (RAS)-Acting Agent Production Growth Rate (2020-2025)
9.7.2 China Renin-Angiotensin-System (RAS)-Acting Agent Production, Revenue, Price and Gross Margin (2020-2025)
10 Key Companies Profile
10.1 Novartis AG
10.1.1 Novartis AG Basic Information
10.1.2 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Overview
10.1.3 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Market Performance
10.1.4 Novartis AG Business Overview
10.1.5 Novartis AG SWOT Analysis
10.1.6 Novartis AG Recent Developments
10.2 Pfizer
10.2.1 Pfizer Basic Information
10.2.2 Pfizer Renin-Angiotensin-System (RAS)-Acting Agent Product Overview
10.2.3 Pfizer Renin-Angiotensin-System (RAS)-Acting Agent Product Market Performance
10.2.4 Pfizer Business Overview
10.2.5 Pfizer SWOT Analysis
10.2.6 Pfizer Recent Developments
10.3 Inc.
10.3.1 Inc. Basic Information
10.3.2 Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Overview
10.3.3 Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Market Performance
10.3.4 Inc. Business Overview
10.3.5 Inc. SWOT Analysis
10.3.6 Inc. Recent Developments
10.4 AstraZeneca plc
10.4.1 AstraZeneca plc Basic Information
10.4.2 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Overview
10.4.3 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Market Performance
10.4.4 AstraZeneca plc Business Overview
10.4.5 AstraZeneca plc Recent Developments
10.5 Merck and Co.
10.5.1 Merck and Co. Basic Information
10.5.2 Merck and Co. Renin-Angiotensin-System (RAS)-Acting Agent Product Overview
10.5.3 Merck and Co. Renin-Angiotensin-System (RAS)-Acting Agent Product Market Performance
10.5.4 Merck and Co. Business Overview
10.5.5 Merck and Co. Recent Developments
10.6 Inc.
10.6.1 Inc. Basic Information
10.6.2 Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Overview
10.6.3 Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Market Performance
10.6.4 Inc. Business Overview
10.6.5 Inc. Recent Developments
10.7 Sanofi S.A.
10.7.1 Sanofi S.A. Basic Information
10.7.2 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Overview
10.7.3 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Market Performance
10.7.4 Sanofi S.A. Business Overview
10.7.5 Sanofi S.A. Recent Developments
10.8 Bristol-Myers Squibb Company
10.8.1 Bristol-Myers Squibb Company Basic Information
10.8.2 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Overview
10.8.3 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Market Performance
10.8.4 Bristol-Myers Squibb Company Business Overview
10.8.5 Bristol-Myers Squibb Company Recent Developments
10.9 Daiichi Sankyo Company,Limited
10.9.1 Daiichi Sankyo Company,Limited Basic Information
10.9.2 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Overview
10.9.3 Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Market Performance
10.9.4 Daiichi Sankyo Company,Limited Business Overview
10.9.5 Daiichi Sankyo Company,Limited Recent Developments
10.10 Takeda Pharmaceutical Company Limited
10.10.1 Takeda Pharmaceutical Company Limited Basic Information
10.10.2 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Overview
10.10.3 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Market Performance
10.10.4 Takeda Pharmaceutical Company Limited Business Overview
10.10.5 Takeda Pharmaceutical Company Limited Recent Developments
10.11 Boehringer lngelheim GmbH
10.11.1 Boehringer lngelheim GmbH Basic Information
10.11.2 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Overview
10.11.3 Boehringer lngelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Market Performance
10.11.4 Boehringer lngelheim GmbH Business Overview
10.11.5 Boehringer lngelheim GmbH Recent Developments
10.12 Johnson and Johnson
10.12.1 Johnson and Johnson Basic Information
10.12.2 Johnson and Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Overview
10.12.3 Johnson and Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Market Performance
10.12.4 Johnson and Johnson Business Overview
10.12.5 Johnson and Johnson Recent Developments
11 Renin-Angiotensin-System (RAS)-Acting Agent Market Forecast by Region
11.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Forecast
11.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Market Size Forecast by Country
11.2.3 Asia Pacific Renin-Angiotensin-System (RAS)-Acting Agent Market Size Forecast by Region
11.2.4 South America Renin-Angiotensin-System (RAS)-Acting Agent Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Renin-Angiotensin-System (RAS)-Acting Agent by Country
12 Forecast Market by Type and by Application (2026-2033)
12.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Renin-Angiotensin-System (RAS)-Acting Agent by Type (2026-2033)
12.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Renin-Angiotensin-System (RAS)-Acting Agent by Type (2026-2033)
12.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Forecast by Application (2026-2033)
12.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales (K MT) Forecast by Application
12.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size (M USD) Forecast by Application (2026-2033)
13 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings